Actinium Pharmaceuticals Statistics
Want to see ATNM full AI Analyst Report?
Actinium Pharmaceuticals (ATNM) Stock Statistics & Valuation Metrics
Total Valuation
Actinium Pharmaceuticals has a market cap or net worth of $49.99M. The enterprise value is -$3.88M.
- Market Cap
- $49.99M
- Enterprise Value
- -$3.88M
Share Statistics
Actinium Pharmaceuticals has 31,441,437 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 31,441,437
- Owned by Insiders
- 7.10%
- Owned by Institutions
- 12.40%
Financial Efficiency
Actinium Pharmaceuticals’s return on equity (ROE) is -4.33 and return on invested capital (ROIC) is -81.40%.
- Return on Equity (ROE)
- -4.33
- Return on Assets (ROA)
- -0.65
- Return on Invested Capital (ROIC)
- -81.40%
- Return on Capital Employed (ROCE)
- -0.83
- Revenue Per Employee
- 3,333.333
- Profits Per Employee
- -1.26M
- Employee Count
- 27
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Actinium Pharmaceuticals is 4.56. Actinium Pharmaceuticals’s PEG ratio is 0.02.
- PE Ratio
- 4.56
- PS Ratio
- 1.47
- PB Ratio
- 1.70
- Price to FCF
- -2.22
- Price to Operating Cash Flow
- -2.27
- PEG Ratio
- 0.02
Income Statement
In the last 12 months, Actinium Pharmaceuticals had revenue of 90.00K and earned -33.89M in profits. Earnings per share was -1.09.
- Revenue
- 90.00K
- Gross Profit
- 90.00K
- Operating Income
- -36.25M
- Pretax Income
- -33.89M
- Net Income
- -33.89M
- EBITDA
- -33.07M
- Earnings Per Share (EPS)
- -1.09
Cash Flow
In the last 12 months, operating cash flow was -22.66M and capital expenditures -584,000, giving a free cash flow of -23.25M billion.
- Operating Cash Flow
- -22.66M
- Free Cash Flow
- -23.25M
- Free Cash Flow per Share
- -0.74
Dividends & Yields
Actinium Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -45.08%
- Earnings Yield
- 21.96%
Stock Price Statistics
- Beta
- 1.66
- 52-Week Price Change
- 31.20%
- 50-Day Moving Average
- 1.27
- 200-Day Moving Average
- 1.12
- Relative Strength Index (RSI)
- 65.26
- Average Volume (3m)
- 183.43K
Important Dates
Actinium Pharmaceuticals upcoming earnings date is Nov 23, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Mar 13, 2026
- Next Earnings Date
- Nov 23, 2026
- Ex-Dividend Date
- ―
Financial Position
Actinium Pharmaceuticals as a current ratio of 6.20, with Debt / Equity ratio of 21.62%
- Current Ratio
- 6.20
- Quick Ratio
- 6.20
- Debt to Market Cap
- 0.02
- Net Debt to EBITDA
- 1.40
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Actinium Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Actinium Pharmaceuticals EV to EBITDA ratio is 1.35, with an EV/FCF ratio of -0.71.
- EV to Sales
- 0.47
- EV to EBITDA
- 1.35
- EV to Free Cash Flow
- -0.71
- EV to Operating Cash Flow
- -0.73
Balance Sheet
Actinium Pharmaceuticals has $36.47M in cash and marketable securities with $1.34M in debt, giving a net cash position of $35.13M billion.
- Cash & Marketable Securities
- $36.47M
- Total Debt
- $1.34M
- Net Cash
- $35.13M
- Net Cash Per Share
- $1.12
- Tangible Book Value Per Share
- $0.97
Margins
Gross margin is 101.13%, with operating margin of 27.23%, and net profit margin of 32.23%.
- Gross Margin
- 101.13%
- Operating Margin
- 27.23%
- Pretax Margin
- 32.23%
- Net Profit Margin
- 32.23%
- EBITDA Margin
- 34.71%
- EBIT Margin
- 32.23%
Analyst Forecast
The average price target for Actinium Pharmaceuticals is $3.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $3.50
- Price Target Upside
- 113.41% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 9
- AI Score
- 62
